CN101528220A - Dmae作为单一制剂用于治疗轻度认知损害 - Google Patents

Dmae作为单一制剂用于治疗轻度认知损害 Download PDF

Info

Publication number
CN101528220A
CN101528220A CNA2007800401804A CN200780040180A CN101528220A CN 101528220 A CN101528220 A CN 101528220A CN A2007800401804 A CNA2007800401804 A CN A2007800401804A CN 200780040180 A CN200780040180 A CN 200780040180A CN 101528220 A CN101528220 A CN 101528220A
Authority
CN
China
Prior art keywords
dimethylaminoethanol
ester
dmae
use according
pyroglutamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800401804A
Other languages
English (en)
Chinese (zh)
Inventor
P·法布雷
C·普日贝尔斯基
B·杜波依斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Publication of CN101528220A publication Critical patent/CN101528220A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CNA2007800401804A 2006-10-31 2007-10-31 Dmae作为单一制剂用于治疗轻度认知损害 Pending CN101528220A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0609548 2006-10-31
FR0609548A FR2907679B1 (fr) 2006-10-31 2006-10-31 Utilisation de dmae pour le traitement de deficit cognitif leger

Publications (1)

Publication Number Publication Date
CN101528220A true CN101528220A (zh) 2009-09-09

Family

ID=38050144

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800401804A Pending CN101528220A (zh) 2006-10-31 2007-10-31 Dmae作为单一制剂用于治疗轻度认知损害

Country Status (18)

Country Link
US (1) US8207218B2 (enExample)
EP (1) EP2083814B1 (enExample)
JP (1) JP2010508253A (enExample)
KR (1) KR20090082428A (enExample)
CN (1) CN101528220A (enExample)
AR (1) AR063764A1 (enExample)
AU (1) AU2007316137A1 (enExample)
BR (1) BRPI0718263A2 (enExample)
CA (1) CA2667983A1 (enExample)
FR (1) FR2907679B1 (enExample)
IL (1) IL198463A0 (enExample)
MA (1) MA30925B1 (enExample)
MX (1) MX2009004682A (enExample)
NO (1) NO20092099L (enExample)
RU (1) RU2009120137A (enExample)
TN (1) TN2009000159A1 (enExample)
WO (1) WO2008053011A1 (enExample)
ZA (1) ZA200903626B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150157046A1 (en) * 2013-12-10 2015-06-11 Lifewave, Inc. Nutritional product composition for the mind
EP4736750A3 (en) * 2022-05-02 2026-07-15 Emocog Co., Ltd. Test method and apparatus for evaluating cognitive function decline

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US20060211721A1 (en) * 2005-03-21 2006-09-21 Roberts Alan R Nutraceutical formulation of a cognitive enhancement system

Also Published As

Publication number Publication date
TN2009000159A1 (fr) 2010-10-18
BRPI0718263A2 (pt) 2014-01-07
ZA200903626B (en) 2010-07-28
MA30925B1 (fr) 2009-11-02
FR2907679A1 (fr) 2008-05-02
US8207218B2 (en) 2012-06-26
WO2008053011A1 (fr) 2008-05-08
RU2009120137A (ru) 2010-12-10
AU2007316137A1 (en) 2008-05-08
US20090298908A1 (en) 2009-12-03
EP2083814A1 (fr) 2009-08-05
IL198463A0 (en) 2010-02-17
CA2667983A1 (fr) 2008-05-08
AR063764A1 (es) 2009-02-18
FR2907679B1 (fr) 2009-10-30
EP2083814B1 (fr) 2013-03-20
JP2010508253A (ja) 2010-03-18
NO20092099L (no) 2009-07-17
MX2009004682A (es) 2009-09-28
KR20090082428A (ko) 2009-07-30

Similar Documents

Publication Publication Date Title
AU2021204465B2 (en) Extended release pharmaceutical compositions of levetiracetam
Shim et al. Role of nitric oxide synthase inhibitors and NMDA receptor antagonist in nicotine-induced behavioral sensitization in the rat
US8071610B2 (en) Compositions and methods for enhancing brain function
US8883814B2 (en) Compositions and methods for enhancing brain function
JPH03500897A (ja) 精神分裂病治療用組成物
Deutsch et al. Methylene blue adjuvant therapy of schizophrenia
JPH02500975A (ja) コリン作動性ニューロン欠損状態でのモノアミンアクリジン類の投与
Lee et al. Pharmacological management of the psychiatric aspects of traumatic brain injury
JP2006502188A (ja) 年齢関連記憶欠陥（ａａｍｉ）、中程度認識欠陥（ｍｃｉ）、および痴呆を細胞周期インヒビターで処置する方法
JPH02240021A (ja) 抑うつ障害の治療用に適した制御放出製薬組成物
Ad Hoc Review Committee: et al. Do caffeine‐containing analgesics promote dependence? A review and evaluation
AU664768B2 (en) Nadh and nadph as drugs for treating alzheimer's disease
Bruce‐Jones et al. Indomethacin and cognitive function in healthy elderly volunteers.
Wroblewski et al. Pharmacological treatment of arousal and cognitive deficits
Boller et al. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results
JPH1045582A (ja) アルツハイマー病の早期発病患者を治療するためのカルニチン誘導体を含む医薬
Amore et al. Long-term treatment of geropsychiatric depressed patients with venlafaxine
Doyle et al. Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series
US8207218B2 (en) DMAE as sole agent for the treatment of mild cognitive impairment
US5747494A (en) Pharmaceutical compositions for the treatment of depressive disorders
Thal Physostigmine in Alzheimer’s disease
CA3204360A1 (en) Use of mglur5 antagonists for treating gambling disorder
US20040058947A1 (en) Composition for the prevention or treatment of learning disorders in children suffering from attention deficit/hyperactive disorder
HK1135909A (en) Dmae as sole agent for the treatment of mild cognitive impairment
Whitehouse Donepezil

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135909

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090909

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1135909

Country of ref document: HK